-
Mashup Score: 1BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS FEBRUARY 12, 2025 | Biogen - 10 hour(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet
-
Mashup Score: 8
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: With Eisai, we announced the completion of the filing submission with the U.S. Food and Drug Administration for our Alzheimer’s treatment. Learn more about this milestone: https://t.co/IrytLMA1sj https://t.co/CrBkx5PPfp
-
-
Mashup Score: 3
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
Our CEO, Chris Viehbacher, is sharing Biogen’s strategy and key growth drivers at the 43rd Annual J.P. Morgan Healthcare Conference. Join the webcast live on January 14, at 9:45am PT/12:45pm ET. Register here: https://t.co/WJBTJ4y0ER https://t.co/fVmt4gKQZa
-
-
Mashup Score: 6
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: At #ACR24, with @ucb_news, we shared detailed results from a Phase 3 study of our investigational therapy for moderate-to-severe systemic lupus erythematosus (SLE). Read more: https://t.co/zl4MyRMhB9 https://t.co/wQD8Px6Zkx
-
-
Mashup Score: 2Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease | Biogen - 2 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: With Eisai, we received a positive opinion from the Committee for Medicinal Products for Human Use, part of the European Medicines Agency. This represents a significant advancement in our commitment to people living with Alzheimer’s disease. https://t.co/K5YN9neuy8 https://t.co/S0k4Chml6a
-
-
Mashup Score: 2Biogen Reports Third Quarter 2024 Results | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: Biogen will report Q3 2024 financial results today before markets open in the U.S.: https://t.co/uVwbVfc0T0 #Earnings $BIIB https://t.co/IPEA1WXSl0
-
-
Mashup Score: 1
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: We announced a new multi-target research collaboration with Neomorph to discover & develop molecular glue degraders for priority targets in Alzheimer’s, rare, and immunological diseases. Read the news: https://t.co/BmQhgYJ1F9 https://t.co/ChyaLtQ9lT
-
-
Mashup Score: 7
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: We announced positive Phase 2 results for our investigational treatment for people living with IgA nephropathy at #KidneyWk. Read on: https://t.co/iz0faOSagX https://t.co/fo1I1S2EKN
-
-
Mashup Score: 3Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: We’re presenting new data from our #AlzheimersDisease research portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (#CTAD24) annual conference in Madrid, Spain. Learn more: https://t.co/ibinrNGO75 https://t.co/M8fSJeSjMR
-
-
Mashup Score: 1Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024 | Biogen - 3 month(s) ago
The Investor Relations website contains information about Biogen’s business for stockholders, potential investors, and financial analysts.
Source: investors.biogen.comCategories: General Medicine News, PayerTweet-
#News: We’re presenting late breaker and new investigational data at @ASNKidney Week in San Diego. Learn More: https://t.co/SIKBFJumoa https://t.co/wulnaR9mgb
-
Biogen will report Q4 and full year 2024 financial results on February 12 before markets open in the U.S. Learn more: https://t.co/Il4LGtOZ4D #Earnings $BIIB https://t.co/kKeB8R4yJc